Avidity Biosciences Announces New Stock Option Grants
Avidity Biosciences, Inc. (Nasdaq: RNA) has recently taken a significant step forward by announcing stock option awards as part of its commitment to attract talented individuals. This initiative focuses on enhancing the company’s development and delivery of RNA-based therapeutics, known as Antibody Oligonucleotide Conjugates (AOCs™). The decision to grant these options reflects Avidity's dedication to building a robust team as it continues to innovate within the biopharmaceutical industry.
Details of the Inducement Awards
On a pivotal date, Avidity made the announcement regarding non-qualified stock options, where the Human Capital Management Committee awarded a total of 263,000 shares alongside 131,450 restricted stock units (RSUs) to thirty-three new non-executive employees. This is all part of the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan. Such grants are designed to entice competent professionals to join the company during a crucial phase of growth.
Understanding the Employment Inducement Plan
The 2022 Inducement Plan is tailored specifically for individuals entering the company who have not been Avidity employees before, or who have recently completed a bona fide period away from the workforce. This plan aligns with Nasdaq Listing Rule 5635(c)(4), underlining the company's compliance and strategic hiring approach. By doing so, Avidity aims to cultivate a workforce that is both skilled and aligned with its mission to innovate in RNA therapeutics.
Participation Conditions for the Awards
The stock options granted come with a set exercise price of $26.66, which matches the closing price of Avidity's common stock on the Nasdaq Global Market recently. The vesting schedule is structured over four years, where 25% vests on the first anniversary, followed by equal monthly vesting amounts for the remainder of the period. Continual employment is a requisite condition for each employee as they progress through their vesting timelines.
About Avidity Biosciences
Avidity Biosciences is on a mission to improve the quality of life through innovative RNA therapeutics utilizing its proprietary AOC platform. This novel approach synergizes the targeting capabilities of monoclonal antibodies with the precision inherent in oligonucleotide therapies. Currently, Avidity is pioneering therapy development targeting rare neuromuscular diseases, including myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy.
Expanding Treatment Opportunities
Moreover, the company is actively engaging in developing additional therapeutic candidates in the cardiology domain with the aim of addressing genetic cardiomyopathies. Their efforts not only enhance treatment options but also potentially broaden the scope of their AOC technology through various partnerships in fields such as cardiology and immunology.
Investor Contact Information
For those interested in learning more about Avidity and its initiatives, Kat Lange is the point of contact for investor relations, reachable at (619) 837-5014. The company encourages any inquiries regarding their progress and engagement with the community.
Media Inquiries
For media inquiries, Avidity emphasizes the importance of transparent communication, and inquiries can be directed to their media contact, also reachable at (619) 837-5016.
Frequently Asked Questions
What are the latest stock option grants by Avidity Biosciences?
Avidity has announced non-qualified stock options for 263,000 shares and 131,450 RSUs, aimed at new non-executive employees as part of their inducement plan.
What is the purpose of the 2022 Inducement Plan?
The plan is designed to attract and retain talent by granting equity awards to individuals who were not previously employed by Avidity.
How does the vesting schedule work for these awards?
The options will vest over four years, with a quarter vesting after the first year and the remaining shares vesting monthly over the following three years.
What are Avidity’s main therapeutic focuses?
Avidity is focusing on RNA therapeutics, particularly targeting rare neuromuscular diseases and advancing candidates in the precision cardiology sector.
Who can inquiries about investor and media relations be directed to?
Inquiries for investor relations can be directed to Kat Lange, while media inquiries can be addressed to the company's media contact.
